Crossmark

How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR+/HER2− Breast Cancer in the Post-RxPONDER Era?

Crossref DOI link: https://doi.org/10.1245/s10434-022-12193-w

Published Online: 2022-07-18

Published Print: 2022-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pilewskie, Melissa

Sevilimedu, Varadan

Eroglu, Idil

Le, Tiana

Wang, Rui

Morrow, Monica

Braunstein, Lior Z.
License Information

Text and Data Mining valid from 2022-07-18

Version of Record valid from 2022-07-18
More Information

Article History

Received: 27 June 2022

Accepted: 29 June 2022

First Online: 18 July 2022

Disclosures

: The preparation of this study was supported in part by NIH/NCI Cancer Center Support Grant No. P30CA008748 to Memorial Sloan Kettering Cancer Center. Dr. Monica Morrow has received honoraria from Roche and Exact Sciences. All other authors have no relevant conflicts of interest to disclose.

Document is current

Any future updates will be listed below